Symphogen
Anne-Sofie Voss has a diverse work experience in the pharmaceutical industry. Anne-Sofie started their career as a Production Chemist at Statens Serums Institut in 2006, where they worked until 2007. Anne-Sofie then moved on to Ferrosan, where they worked as a Production Chemist from 2007 to 2011. In 2014, they joined Novo Nordisk as a Pilot Scientist in the Oral Pilot Plant, and they remained in that role until 2018. Since 2018, Anne-Sofie Voss has been working at Symphogen, starting as a Scientist and then progressing to the role of Senior Scientist in November 2021.
Anne-Sofie Voss attended Danmarks Farmaceutiske Universitet from 2000 to 2006.
Symphogen
3 followers
Symphogen is a clinical-stage antibody oncology focused company with a differentiated product pipeline and significant commercial opportunities. Inspired by nature, led by science and driven by people, we passionately strive to make that discovery that may have great effect on the lives of patients, their families, and their caregivers. Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb and mAb mixture products candidates. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations. We are headquartered in Denmark with operations in the US.